FDA
-
-
-
-
-
-
-
IN8bio prices $40.2 million private placement for cancer therapy
-
-
-
-
-
-
-
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of
-
-
-
-
-
-
-
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
IN8bio, Inc (INAB) Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
-
-
-
-
-
-
-
IN8bio, Inc (INAB) Provides Clinical Update from the Ongoing Phase 1 Trial of INB-100
-
-
-
-
-
-
-
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

